Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation with Insulin Resistance, Inflammation, and Liver Histology

Background and Aim Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effe...

Full description

Saved in:
Bibliographic Details
Published inJournal of investigative medicine Vol. 63; no. 7; pp. 871 - 877
Main Authors Boga, Salih, Alkim, Huseyin, Koksal, Ali Riza, Bayram, Mehmet, Ozguven, Muveddet Banu Yilmaz, Ergun, Meltem, Neijmann, Sebnem Tekin, Ozgon, Gulay, Alkim, Canan
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.10.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background and Aim Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD. Patients and Methods Plasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls. Results The HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition (P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR. Conclusions Our data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH.
AbstractList Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD. Plasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls. The HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition (P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR. Our data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH.
Background and Aim Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD. Patients and Methods Plasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls. Results The HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition ( P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR. Conclusions Our data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH.
BACKGROUND AND AIMCardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD.PATIENTS AND METHODSPlasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls.RESULTSThe HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition (P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR.CONCLUSIONSOur data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH.
Author Alkim, Canan
Koksal, Ali Riza
Neijmann, Sebnem Tekin
Ozgon, Gulay
Ozguven, Muveddet Banu Yilmaz
Ergun, Meltem
Boga, Salih
Alkim, Huseyin
Bayram, Mehmet
Author_xml – sequence: 1
  givenname: Salih
  surname: Boga
  fullname: Boga, Salih
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
– sequence: 2
  givenname: Huseyin
  surname: Alkim
  fullname: Alkim, Huseyin
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
– sequence: 3
  givenname: Ali Riza
  surname: Koksal
  fullname: Koksal, Ali Riza
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
– sequence: 4
  givenname: Mehmet
  surname: Bayram
  fullname: Bayram, Mehmet
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
– sequence: 5
  givenname: Muveddet Banu Yilmaz
  surname: Ozguven
  fullname: Ozguven, Muveddet Banu Yilmaz
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
– sequence: 6
  givenname: Meltem
  surname: Ergun
  fullname: Ergun, Meltem
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
– sequence: 7
  givenname: Sebnem Tekin
  surname: Neijmann
  fullname: Neijmann, Sebnem Tekin
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
– sequence: 8
  givenname: Gulay
  surname: Ozgon
  fullname: Ozgon, Gulay
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
– sequence: 9
  givenname: Canan
  surname: Alkim
  fullname: Alkim, Canan
  organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26244718$$D View this record in MEDLINE/PubMed
BookMark eNp9kctu1TAQhi1URC_wBgh5yaIpdi5Owq4qlB50uKiCdTRxxue4cuziSYryNH3VupwDQiyYzYys7_9Hnv-YHfjgkbGXUpxJ0dZvPq4-nYm_Ky_EE3Yka9FkTa7qgzSLRmZV1bSH7JjoJiGqavNn7DBXeVnWsjli9yuvIwLhwL86oBH4Gu_QEQ-Gn9MyjjhFq_k7m4bt4iBurLceufX8c_DgdNgGl4BLmKaFr-0dxgTTo-Nbfo0OJhs8_2mnLV95ml3SXSNZmsBrPE1vxsE4_qJOOfhhb3GViODCZnnOnhpwhC_2_YR9v3z_7eIqW3_5sLo4X2e6KNspUzD0WNRGiUb0mD5agpGqMWWle0gXyBHyqlGy70tTFGhQIepelqXu80EZLE7Y653vbQw_ZqSpGy1pdA48hpk6WUvVFnXVioSWO1THQBTRdLfRjhCXToruMZouRdP9G02SvdpvmPsRhz-i31kkQO4Agg12N2GO6b70f9MH9KqdCQ
CitedBy_id crossref_primary_10_3390_antiox11050880
crossref_primary_10_1007_s13312_017_1143_x
crossref_primary_10_1016_j_apsb_2023_05_020
crossref_primary_10_1039_C9RA00669A
crossref_primary_10_1016_j_cld_2017_08_009
crossref_primary_10_1186_s12967_020_02637_w
crossref_primary_10_3390_ijms21249646
crossref_primary_10_1089_ars_2016_6742
crossref_primary_10_1093_jn_nxaa032
crossref_primary_10_3390_medicina56110622
crossref_primary_10_1002_jcb_28021
Cites_doi 10.1016/j.jchromb.2006.09.023
10.1016/S0002-9149(01)02063-X
10.1177/1358836X0501000106
10.1016/j.jhep.2008.06.018
10.1016/j.jhep.2004.03.016
10.1161/01.CIR.98.18.1842
10.1111/j.1365-2362.2007.01814.x
10.1016/j.cgh.2008.11.005
10.2215/CJN.11291210
10.1681/ASN.V103594
10.1111/j.1572-0241.2007.01774.x
10.1016/S0140-6736(01)07217-8
10.3109/00365520903443852
10.2337/dc06-9913
10.1042/cs1000161
10.1016/j.numecd.2010.10.003
10.1097/00005344-199904000-00020
10.1016/j.atherosclerosis.2009.10.034
10.1001/jama.287.11.1420
10.1161/01.CIR.99.24.3092
10.1177/1358863X10364552
10.1016/S0008-6363(03)00500-5
10.1177/0148607108321702
10.1097/00005344-199204002-00018
10.1016/j.ijcard.2006.11.058
10.1161/01.CIR.0000111245.75752.C6
10.1042/CS20030285
10.1007/s12020-012-9712-1
10.1016/S0735-1097(01)01318-3
10.1159/000336669
10.1016/0140-6736(92)90865-Z
10.1210/jc.2006-2643
10.1002/hep.20701
10.1007/s00125-002-0975-6
10.1016/j.metabol.2010.07.027
10.1161/01.RES.0000181286.44222.61
ContentType Journal Article
Copyright 2015 American Federation for Medical Research
Copyright_xml – notice: 2015 American Federation for Medical Research
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1097/JIM.0000000000000230
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1708-8267
EndPage 877
ExternalDocumentID 10_1097_JIM_0000000000000230
26244718
10.1097_JIM.0000000000000230
Genre Journal Article
GroupedDBID ---
.55
.GJ
.Z2
0-V
0R~
1CY
36B
3O-
3V.
53G
5GY
5VS
7X7
88E
8FI
8FJ
8G5
AAEWN
AAKAS
AATAA
AAWTL
AAYAA
ABBUW
ABJNI
ABPNF
ABRHV
ABUWG
ABVAJ
ABWEH
ABZAD
ACDDN
ACGFS
ACOXC
ACUIR
ACWDW
ACWRI
ADBBV
ADBIZ
ADMRH
ADZCM
AEAXR
AENEX
AEXNY
AFKRA
AFTRI
AGKLV
AHMBA
AHQMW
AIZYK
AJYBZ
ALIPV
ALKDR
ALMA_UNASSIGNED_HOLDINGS
ALSLI
ALTZF
ARALO
ARTOV
AZQEC
BENPR
BGRYB
BKSCU
BOMFT
BPACV
BPHCQ
BVXVI
C45
CCPQU
CS3
DU5
DWQXO
E.X
EBS
EJD
EMB
EX3
F5P
FHBDP
FL-
FYUFA
GNUQQ
GUQSH
HAJ
HMCUK
HZ~
IN~
J8X
KD2
M0O
M1P
M2O
NTWIH
O9-
OVD
P2P
PQQKQ
PROAC
PSQYO
RHF
RHI
RMJ
S4S
SFC
SJN
SV3
TEORI
TWG
UKHRP
V2I
W3M
WH7
WOQ
WOW
X7M
ZXP
ABKLS
ABKRM
ACARO
ALKWR
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c349t-6adbe37f6080be0024af168f45cba5582ea25861bb4f33efe6eecb144cb2d6fe3
ISSN 1081-5589
IngestDate Fri Aug 16 23:30:23 EDT 2024
Fri Aug 23 03:45:11 EDT 2024
Sat Sep 28 08:03:46 EDT 2024
Tue Jul 16 20:34:19 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords HOMA-IR
NAFLD
hs-CRP
asymmetric dimethylarginine
IL-6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c349t-6adbe37f6080be0024af168f45cba5582ea25861bb4f33efe6eecb144cb2d6fe3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 26244718
PQID 1716937590
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_1716937590
crossref_primary_10_1097_JIM_0000000000000230
pubmed_primary_26244718
sage_journals_10_1097_JIM_0000000000000230
PublicationCentury 2000
PublicationDate 20151000
2015-Oct
2015-10-00
20151001
PublicationDateYYYYMMDD 2015-10-01
PublicationDate_xml – month: 10
  year: 2015
  text: 20151000
PublicationDecade 2010
PublicationPlace Los Angeles, CA
PublicationPlace_xml – name: Los Angeles, CA
– name: England
PublicationTitle Journal of investigative medicine
PublicationTitleAlternate J Investig Med
PublicationYear 2015
Publisher SAGE Publications
Publisher_xml – name: SAGE Publications
References Vizzutti, Romanelli, Arena 2007; 37
Cavusoglu, Ruwende, Chopra 2010; 210
Zoccali, Bode-Böger, Mallamaci 2001; 358
Ong, Pitts, Younossi 2008; 49
Milic, Stimac 2012; 30
Horowitz, Heresztyn 2007; 851
Altinova, Arslan, Sepici-Dincel 2007; 92
Vallance, Leone, Calver 1992; 20
Colak, Senates, Yesil 2013; 43
Kielstein, Böger, Bode-Böger 1999; 10
Garcia, Perez, Maas 2007; 122
Sydow, Mondon, Cooke 2005; 10
Tripepi, Mattace Raso, Sijbrands 2011; 6
Siervo, Corander, Stranges 2011; 21
Schnabel, Blankenberg, Lubos 2005; 97
Abbasi, Asagmi, Cooke 2001; 88
Böger, Lentz, Bode-Böger 2001; 100
Lundman, Eriksson, Stühlinger 2001; 38
Kleiner, Brunt, Van Natta 2005; 41
Rafiq, Bai, Fang 2009; 7
Tsikas, Rode, Becker 2003; 38
Vallance, Leone, Calver 1992; 339
Wilson, Shin, Weatherby 2010; 15
Kasumov, Edmison, Dasarathy 2011; 60
Wieckowska, Papouchado, Li 2008; 103
Stuhlinger, Abbasi, Chu 2002; 2877
Grundy, Brewer, Cleeman 2004; 109
Ito, Tsao, Adimoolam 1999; 99
Videla, Rodrigo, Orellana 2004; 106
Böger 2003; 59
2006; 29
Surdacki, Nowicki, Sandmann 1999; 33
Lluch, Torondel, Medina 2004; 41
Boger, Bode-Boger, Szuba 1998; 98
Chan, Chan 2002; 45
Richir, Bouwman, Teerlink 2008; 32
Onat, Hergenç, Can 2008; 36
Kukla, Zwirska-Korczala, Hartleb 2010; 45
bibr12-JIM.0000000000000230
bibr24-JIM.0000000000000230
bibr29-JIM.0000000000000230
Onat A (bibr32-JIM.0000000000000230) 2008; 36
bibr7-JIM.0000000000000230
bibr31-JIM.0000000000000230
bibr33-JIM.0000000000000230
bibr38-JIM.0000000000000230
bibr26-JIM.0000000000000230
bibr19-JIM.0000000000000230
bibr34-JIM.0000000000000230
bibr22-JIM.0000000000000230
bibr27-JIM.0000000000000230
bibr4-JIM.0000000000000230
bibr15-JIM.0000000000000230
bibr10-JIM.0000000000000230
Tsikas D (bibr13-JIM.0000000000000230) 2003; 38
bibr2-JIM.0000000000000230
bibr17-JIM.0000000000000230
bibr36-JIM.0000000000000230
bibr9-JIM.0000000000000230
bibr3-JIM.0000000000000230
bibr8-JIM.0000000000000230
bibr37-JIM.0000000000000230
bibr28-JIM.0000000000000230
bibr25-JIM.0000000000000230
bibr20-JIM.0000000000000230
bibr6-JIM.0000000000000230
bibr5-JIM.0000000000000230
bibr14-JIM.0000000000000230
bibr1-JIM.0000000000000230
bibr30-JIM.0000000000000230
bibr21-JIM.0000000000000230
bibr23-JIM.0000000000000230
bibr18-JIM.0000000000000230
bibr11-JIM.0000000000000230
bibr35-JIM.0000000000000230
bibr16-JIM.0000000000000230
References_xml – volume: 60
  start-page: 776
  issue: 6
  year: 2011
  end-page: 781
  article-title: Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease
  publication-title: Metabolism
  contributor:
    fullname: Dasarathy
– volume: 10
  year: 2005
  article-title: Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA
  publication-title: Vasc Med
  contributor:
    fullname: Cooke
– volume: 38
  start-page: 111
  issue: 1
  year: 2001
  end-page: 116
  article-title: Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine
  publication-title: J Am Coll Cardiol
  contributor:
    fullname: Stühlinger
– volume: 32
  start-page: 613
  issue: 6
  year: 2008
  end-page: 621
  article-title: The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function
  publication-title: JPEN J Parenter Enteral Nutr
  contributor:
    fullname: Teerlink
– volume: 29
  start-page: 1955
  issue: 8
  year: 2006
  end-page: 1962
  article-title: ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control
  publication-title: Diabetes Care
– volume: 21
  start-page: 1
  issue: 1
  year: 2011
  end-page: 10
  article-title: Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA)
  publication-title: Nutr Metab Cardiovasc Dis
  contributor:
    fullname: Stranges
– volume: 109
  start-page: 433
  issue: 3
  year: 2004
  end-page: 438
  article-title: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition
  publication-title: Circulation
  contributor:
    fullname: Cleeman
– volume: 7
  start-page: 234
  issue: 2
  year: 2009
  end-page: 238
  article-title: Long-term follow-up of patients with nonalcoholic fatty liver
  publication-title: Clin Gastroenterol Hepatol
  contributor:
    fullname: Fang
– volume: 122
  start-page: 176
  issue: 2
  year: 2007
  end-page: 178
  article-title: Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome
  publication-title: Int J Cardiol
  contributor:
    fullname: Maas
– volume: 20
  year: 1992
  article-title: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis
  publication-title: J Cardiovasc Pharmacol
  contributor:
    fullname: Calver
– volume: 10
  start-page: 594
  issue: 3
  year: 1999
  end-page: 600
  article-title: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease
  publication-title: J Am Soc Nephrol
  contributor:
    fullname: Bode-Böger
– volume: 2877
  start-page: 1420
  issue: 11
  year: 2002
  end-page: 1426
  article-title: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor
  publication-title: JAMA
  contributor:
    fullname: Chu
– volume: 36
  start-page: 7
  issue: 1
  year: 2008
  end-page: 13
  article-title: Serum asymmetric dimethylarginine levels among Turks: association with metabolic syndrome in women and tendency to decrease in smokers
  publication-title: Turk Kardiyol Dern Ars
  contributor:
    fullname: Can
– volume: 30
  start-page: 158
  issue: 2
  year: 2012
  end-page: 162
  article-title: Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment
  publication-title: Dig Dis
  contributor:
    fullname: Stimac
– volume: 851
  start-page: 42
  issue: 1–2
  year: 2007
  end-page: 50
  article-title: An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations
  publication-title: J Chromatogr B Analyt Technol Biomed Life Sci
  contributor:
    fullname: Heresztyn
– volume: 15
  start-page: 267
  issue: 4
  year: 2010
  end-page: 274
  article-title: Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease
  publication-title: Vasc Med
  contributor:
    fullname: Weatherby
– volume: 38
  start-page: 1063
  issue: 4
  year: 2003
  end-page: 1064
  article-title: Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease
  publication-title: Hepatology
  contributor:
    fullname: Becker
– volume: 37
  start-page: 509
  issue: 6
  year: 2007
  end-page: 515
  article-title: ADMA correlates with portal pressure in patients with compensated cirrhosis
  publication-title: Eur J Clin Invest
  contributor:
    fullname: Arena
– volume: 59
  start-page: 824
  issue: 4
  year: 2003
  end-page: 833
  article-title: The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
  publication-title: Cardiovasc Res
  contributor:
    fullname: Böger
– volume: 43
  start-page: 100
  issue: 1
  year: 2013
  end-page: 107
  article-title: Assessment of endothelial function in patients with nonalcoholic fatty liver disease
  publication-title: Endocrine
  contributor:
    fullname: Yesil
– volume: 98
  start-page: 1842
  year: 1998
  end-page: 1847
  article-title: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia
  publication-title: Circulation
  contributor:
    fullname: Szuba
– volume: 41
  start-page: 1313
  issue: 6
  year: 2005
  end-page: 1321
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
  contributor:
    fullname: Van Natta
– volume: 88
  start-page: 1201
  issue: 10
  year: 2001
  end-page: 1203
  article-title: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus
  publication-title: Am J Cardiol
  contributor:
    fullname: Cooke
– volume: 103
  year: 2008
  article-title: Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis
  publication-title: Am J Gastroenterol
  contributor:
    fullname: Li
– volume: 358
  start-page: 2113
  issue: 9299
  year: 2001
  end-page: 2117
  article-title: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
  publication-title: Lancet
  contributor:
    fullname: Mallamaci
– volume: 106
  start-page: 261
  issue: 3
  year: 2004
  end-page: 268
  article-title: Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients
  publication-title: Clin Sci (Lond)
  contributor:
    fullname: Orellana
– volume: 210
  start-page: 226
  issue: 1
  year: 2010
  end-page: 231
  article-title: Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography
  publication-title: Atherosclerosis
  contributor:
    fullname: Chopra
– volume: 45
  start-page: 1609
  issue: 12
  year: 2002
  end-page: 1616
  article-title: Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
  publication-title: Diabetologia
  contributor:
    fullname: Chan
– volume: 6
  start-page: 1714
  issue: 7
  year: 2011
  end-page: 1721
  article-title: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients
  publication-title: Clin J Am Soc Nephrol
  contributor:
    fullname: Sijbrands
– volume: 92
  start-page: 1881
  issue: 5
  year: 2007
  end-page: 1885
  article-title: Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations
  publication-title: J Clin Endocrinol Metab
  contributor:
    fullname: Sepici-Dincel
– volume: 45
  start-page: 235
  issue: 2
  year: 2010
  end-page: 242
  article-title: Serum chemerin and vaspin in non-alcoholic fatty liver disease
  publication-title: Scand J Gastroenterol
  contributor:
    fullname: Hartleb
– volume: 49
  start-page: 608
  issue: 4
  year: 2008
  end-page: 612
  article-title: Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
  publication-title: J Hepatol
  contributor:
    fullname: Younossi
– volume: 100
  start-page: 161
  issue: 2
  year: 2001
  end-page: 167
  article-title: Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans
  publication-title: Clin Sci (Lond)
  contributor:
    fullname: Bode-Böger
– volume: 99
  start-page: 3092
  issue: 24
  year: 1999
  end-page: 3095
  article-title: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase
  publication-title: Circulation
  contributor:
    fullname: Adimoolam
– volume: 41
  start-page: 55
  issue: 1
  year: 2004
  end-page: 59
  article-title: Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis
  publication-title: J Hepatol
  contributor:
    fullname: Medina
– volume: 339
  start-page: 572
  issue: 8793
  year: 1992
  end-page: 575
  article-title: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
  publication-title: Lancet
  contributor:
    fullname: Calver
– volume: 97
  start-page: e53
  issue: 5
  year: 2005
  end-page: e59
  article-title: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study
  publication-title: Circ Res
  contributor:
    fullname: Lubos
– volume: 33
  start-page: 652
  issue: 4
  year: 1999
  end-page: 658
  article-title: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension
  publication-title: J Cardiovasc Pharmacol
  contributor:
    fullname: Sandmann
– ident: bibr7-JIM.0000000000000230
  doi: 10.1016/j.jchromb.2006.09.023
– ident: bibr14-JIM.0000000000000230
  doi: 10.1016/S0002-9149(01)02063-X
– volume: 36
  start-page: 7
  issue: 1
  year: 2008
  ident: bibr32-JIM.0000000000000230
  publication-title: Turk Kardiyol Dern Ars
  contributor:
    fullname: Onat A
– ident: bibr11-JIM.0000000000000230
  doi: 10.1177/1358836X0501000106
– ident: bibr3-JIM.0000000000000230
  doi: 10.1016/j.jhep.2008.06.018
– ident: bibr27-JIM.0000000000000230
  doi: 10.1016/j.jhep.2004.03.016
– ident: bibr6-JIM.0000000000000230
  doi: 10.1161/01.CIR.98.18.1842
– ident: bibr28-JIM.0000000000000230
  doi: 10.1111/j.1365-2362.2007.01814.x
– ident: bibr2-JIM.0000000000000230
  doi: 10.1016/j.cgh.2008.11.005
– ident: bibr37-JIM.0000000000000230
  doi: 10.2215/CJN.11291210
– ident: bibr8-JIM.0000000000000230
  doi: 10.1681/ASN.V103594
– ident: bibr17-JIM.0000000000000230
  doi: 10.1111/j.1572-0241.2007.01774.x
– ident: bibr23-JIM.0000000000000230
  doi: 10.1016/S0140-6736(01)07217-8
– ident: bibr38-JIM.0000000000000230
  doi: 10.3109/00365520903443852
– ident: bibr18-JIM.0000000000000230
  doi: 10.2337/dc06-9913
– ident: bibr35-JIM.0000000000000230
  doi: 10.1042/cs1000161
– ident: bibr4-JIM.0000000000000230
  doi: 10.1016/j.numecd.2010.10.003
– ident: bibr36-JIM.0000000000000230
  doi: 10.1097/00005344-199904000-00020
– ident: bibr10-JIM.0000000000000230
  doi: 10.1016/j.atherosclerosis.2009.10.034
– volume: 38
  start-page: 1063
  issue: 4
  year: 2003
  ident: bibr13-JIM.0000000000000230
  publication-title: Hepatology
  contributor:
    fullname: Tsikas D
– ident: bibr29-JIM.0000000000000230
  doi: 10.1001/jama.287.11.1420
– ident: bibr34-JIM.0000000000000230
  doi: 10.1161/01.CIR.99.24.3092
– ident: bibr9-JIM.0000000000000230
  doi: 10.1177/1358863X10364552
– ident: bibr24-JIM.0000000000000230
  doi: 10.1016/S0008-6363(03)00500-5
– ident: bibr12-JIM.0000000000000230
  doi: 10.1177/0148607108321702
– ident: bibr5-JIM.0000000000000230
  doi: 10.1097/00005344-199204002-00018
– ident: bibr31-JIM.0000000000000230
  doi: 10.1016/j.ijcard.2006.11.058
– ident: bibr19-JIM.0000000000000230
  doi: 10.1161/01.CIR.0000111245.75752.C6
– ident: bibr16-JIM.0000000000000230
  doi: 10.1042/CS20030285
– ident: bibr25-JIM.0000000000000230
  doi: 10.1007/s12020-012-9712-1
– ident: bibr33-JIM.0000000000000230
  doi: 10.1016/S0735-1097(01)01318-3
– ident: bibr1-JIM.0000000000000230
  doi: 10.1159/000336669
– ident: bibr21-JIM.0000000000000230
  doi: 10.1016/0140-6736(92)90865-Z
– ident: bibr15-JIM.0000000000000230
  doi: 10.1210/jc.2006-2643
– ident: bibr20-JIM.0000000000000230
  doi: 10.1002/hep.20701
– ident: bibr30-JIM.0000000000000230
  doi: 10.1007/s00125-002-0975-6
– ident: bibr26-JIM.0000000000000230
  doi: 10.1016/j.metabol.2010.07.027
– ident: bibr22-JIM.0000000000000230
  doi: 10.1161/01.RES.0000181286.44222.61
SSID ssj0026592
Score 2.2017636
Snippet Background and Aim Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic...
Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and...
BACKGROUND AND AIMCardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic...
SourceID proquest
crossref
pubmed
sage
SourceType Aggregation Database
Index Database
Publisher
StartPage 871
SubjectTerms Adult
Arginine - analogs & derivatives
Arginine - blood
C-Reactive Protein - metabolism
Case-Control Studies
Female
Humans
Inflammation - pathology
Insulin Resistance
Liver - pathology
Male
Middle Aged
Non-alcoholic Fatty Liver Disease - blood
Title Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation with Insulin Resistance, Inflammation, and Liver Histology
URI https://journals.sagepub.com/doi/full/10.1097/JIM.0000000000000230
https://www.ncbi.nlm.nih.gov/pubmed/26244718
https://search.proquest.com/docview/1716937590
Volume 63
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZpCmMvY_dll6LBnta6iy-y5L1loyUpTShZC3kzki11oY0z6mSQ_pn9vv2LHVnyJU0Y6_JgglGOib_P8neOjs5B6EMqqGJEECcFOjmB6nIn8lLmSEJSHlHhuqqo9jkK-xfByYRMWq3fjayl5UIcJrdb95X8D6pwDnDVu2TvgWxlFE7Ad8AXjoAwHP8JY3i4dU45aMYzEMEzvn-qU4CK5IxevprNdLesBGY13SZ6BS7spe4GUVQJGWkBXjTHhQHHfAFS_FRnaOhqnNpiM0_OxGoHNml9LHMtOTMTfB9kCihltj-WiaDGUFF_pArZb8rfaV3g46fcXOK3Ad9v4CZUAeve9ZXp_dxf5nI1rfMH5lc5N8kG19P98fS2DjLw1Y1h_FB-n9m93jbG4ZIqW665uLY1jOmCpHEIMW2IDqU5R7vMAbeJNmd5O40aNtPGlM1MC5jq7U-3vlhMweKTwdAUvCw_nl1UWi_ZbX8Qbxu-g3Y9GhHaRrtfjkZn4yo6oNe3zW4Q84fKfZ4R_bTNzrqO2nCO1hITC610_hg9sijjnmHsE9SS2VP0YGgxfoZ-VcTFhrjYEBfPFa6Ji-8SF08z3CQuLoiLC75hS9zPuKQt1rTFlra4pu0BbpL2AANlrYmKss_RxfHR-de-YzuFOIkfRAsn5KmQPlUh-D9Cat3JlRsyFZBEcLiZnuQeYaErRKB8XyoZSpkINwgS4aWhkv4L1M7mmXyFsCLMTZiniGAsIF1fyCACn5pyNwQrzO8gp7zv8Q9TECYuEzkAp_guTh30vgQnhplbL8fxTM6XeVwUqvIpiWDMS4NaZdELQXaDbOygjxrG2E46-V8v9fo-g9-gh_WT9ha1FzdL-Q709ULsoR06oXuWn38AzqrNSw
link.rule.ids 315,786,790,27957,27958,31755,33780
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+Plasma+Levels+of+Asymmetric+Dimethylarginine+in+Nonalcoholic+Fatty+Liver+Disease%3A+Relation+with+Insulin+Resistance%2C+Inflammation%2C+and+Liver+Histology&rft.jtitle=Journal+of+investigative+medicine&rft.au=Boga%2C+Salih&rft.au=Alkim%2C+Huseyin&rft.au=Koksal%2C+Ali+Riza&rft.au=Bayram%2C+Mehmet&rft.date=2015-10-01&rft.pub=SAGE+Publications&rft.issn=1081-5589&rft.eissn=1708-8267&rft.volume=63&rft.issue=7&rft.spage=871&rft.epage=877&rft_id=info:doi/10.1097%2FJIM.0000000000000230&rft.externalDocID=10.1097_JIM.0000000000000230
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1081-5589&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1081-5589&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1081-5589&client=summon